Abstract 10789: Single Nucleus Transcriptomic Analysis of Left Atrial Immune Reprogramming in Mitral Valve Disease
Abstract
Background: Mitral valve disease (MVD) leads to chronic left atrial (LA) pressure and volume overload, driving atrial remodeling and fibrosis. The transcriptional states of tissue-resident immune cells in MVD associated LA remodeling remain uncharacterized. We hypothesized that MVD is accompanied by reprogramming of LA resident myeloid and lymphoid populations away from homeostatic transcriptional states. Methods: Single nucleus RNA sequencing (snRNA-seq) was performed on left atrial tissue from 29 patients with MVD and 13 controls. Unsupervised clustering defined myeloid and lymphoid cell states. Differential gene expression (DEG) analyses were performed across disease and control groups. Shared transcriptional themes were identified by cross-cluster DEG intersection. Results: Across all myeloid cells, 4,778 DEGs were identified (FDR<0.05). A shared gene set downregulated in MVD included THBS1 , SLC11A1 , and VCAN , indicating loss of homeostatic phagocytic identity, while HDAC9 , CD36 , AFF3 , and RTN1 were upregulated, suggesting epigenetic dysregulation and altered lipid metabolism. At the cell state level MP_LYVE1hi_MHCIIint was significantly expanded in MVD (p<0.0001, 1,766 DEGs), implicating these cells as candidate disease-associated population. MP_OSM that robustly express anti-inflammatory genes NR4A2 and NR4A3, were significantly depleted. In the lymphoid compartment (531 DEGs), CD4T_te_IFNGhi effector T cells were depleted and NK_CD16_IFNGhi and CD4T_Naive cells expanded (p<0.05), with stable B cell proportions, consistent with erosion of adaptive IFNγ-driven immunity with innate NK compensation. Conclusions: snRNA-seq of human LA tissue indicates that MVD associated atrial remodeling is characterized by loss of homeostatic macrophage identity and a shift from adaptive to innate-like immune responses. MP_LYVE1hi_MHCIIint macrophages represent a candidate disease-associated population, suggesting atrial immune reprogramming as a potential therapeutic target in MVD.